221 related articles for article (PubMed ID: 30420447)
1. Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.
Puerto-Camacho P; Amaral AT; Lamhamedi-Cherradi SE; Menegaz BA; Castillo-Ecija H; Ordóñez JL; Domínguez S; Jordan-Perez C; Diaz-Martin J; Romero-Pérez L; Lopez-Alvarez M; Civantos-Jubera G; Robles-Frías MJ; Biscuola M; Ferrer C; Mora J; Cuglievan B; Schadler K; Seifert O; Kontermann R; Pfizenmaier K; Simón L; Fabre M; Carcaboso ÁM; Ludwig JA; de Álava E
Clin Cancer Res; 2019 Apr; 25(7):2228-2240. PubMed ID: 30420447
[TBL] [Abstract][Full Text] [Related]
2. Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell-Matrix Interactions.
Puerto-Camacho P; Díaz-Martín J; Olmedo-Pelayo J; Bolado-Carrancio A; Salguero-Aranda C; Jordán-Pérez C; Esteban-Medina M; Álamo-Álvarez I; Delgado-Bellido D; Lobo-Selma L; Dopazo J; Sastre A; Alonso J; Grünewald TGP; Bernabeu C; Byron A; Brunton VG; Amaral AT; de Álava E
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955799
[TBL] [Abstract][Full Text] [Related]
3. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
4. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
[TBL] [Abstract][Full Text] [Related]
6. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
[TBL] [Abstract][Full Text] [Related]
7. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
8. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
9. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
Wang S; Hwang EE; Guha R; O'Neill AF; Melong N; Veinotte CJ; Conway Saur A; Wuerthele K; Shen M; McKnight C; Alexe G; Lemieux ME; Wang A; Hughes E; Xu X; Boxer MB; Hall MD; Kung A; Berman JN; Davis MI; Stegmaier K; Crompton BD
Clin Cancer Res; 2019 Jul; 25(14):4552-4566. PubMed ID: 30979745
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
11. Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma.
Twardziok M; Kleinsimon S; Rolff J; Jäger S; Eggert A; Seifert G; Delebinski CI
PLoS One; 2016; 11(9):e0159749. PubMed ID: 27589063
[TBL] [Abstract][Full Text] [Related]
12. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
13. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
[TBL] [Abstract][Full Text] [Related]
14. WT1 regulates angiogenesis in Ewing Sarcoma.
Katuri V; Gerber S; Qiu X; McCarty G; Goldstein SD; Hammers H; Montgomery E; Chen AR; Loeb DM
Oncotarget; 2014 May; 5(9):2436-49. PubMed ID: 24810959
[TBL] [Abstract][Full Text] [Related]
15. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
16. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
17. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium.
Kurmasheva RT; Bandyopadhyay A; Favours E; Pozo VD; Ghilu S; Phelps DA; McGeehan GM; Erickson SW; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2020 Jul; 67(7):e28284. PubMed ID: 32333633
[TBL] [Abstract][Full Text] [Related]
19. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.
Tao Y; Wang R; Lai Q; Wu M; Wang Y; Jiang X; Zeng L; Zhou S; Li Z; Yang T; Yao Y; Wu Y; Yu L; Fu Y; Lai W; Peng Y; Lu Y; Zhang Z; Guo C; Zhang G; Gou L; Yang J
Mol Oncol; 2019 Sep; 13(9):1855-1873. PubMed ID: 31116512
[TBL] [Abstract][Full Text] [Related]
20. An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Aiyer RA; Maywald RL; Buford AS; Doolittle DK; Culotta KS; O'Dorisio JE; Ludwig JA
Mol Cancer Ther; 2015 Jul; 14(7):1591-604. PubMed ID: 25964201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
